Swiss digital therapy specialist Oviva has raised $21 million in second-round financing to help expand the use of smartphone-based tools designed to help people with diabetes manage their c
Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.